Q-omics provides the consensus-scored OR5K2 profile across patient tissues and cancer cell-line models. OR5K2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, OR5K2 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, OR5K2 RNA expression shows 15,538 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUSC, and UVM as cancer lineages where OR5K2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5K2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5K2 survival associations across molecular data types. OR5K2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5K2 RNA expression–survival associations across cancer types. High OR5K2 expression shows unfavorable associations in STAD, TGCT, DLBC and LUSC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for OR5K2 RNA expression.
This table summarizes OR5K2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR5K2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5K2 shows lower tumor expression in LUSC, BLCA, KICH, UCEC, BRCA and LUAD. The LUSC box plot shows higher OR5K2 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p < 0.001).
This table shows molecular features associated with OR5K2 in patient tissues and cancer cell lines. In patient samples, OR5K2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5K2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
